No effective therapies exist for Angelman syndrome (AS)---an imprinting disorder caused by mutations or deletions in the maternal allele of *Ube3a*^[@R1]--[@R3]^. *Ube3a* is biallelically expressed in most tissues of the body; however, in rodents and humans, most neurons express *Ube3a* only from the maternally-inherited allele^[@R4],[@R12]--[@R14]^. This unique epigenetic pattern of regulation suggested that it might be possible to unsilence the dormant paternal *Ube3a* allele in neurons^[@R7],[@R8]^.

To test this possibility, we developed a 384-well high-content screen using primary mouse cortical neurons from *Ube3a-Yellow Fluorescent Protein* (*Ube3a-YFP*) knockin mice^[@R15]^, and searched for drug-like molecules that could unsilence the paternal *Ube3a-YFP* allele ([Fig. 1a](#F1){ref-type="fig"}). This screen was based on our observation that the imprinting of *Ube3a-YFP* was maintained *in vitro* in cultured embryonic cortical neurons. Notably, *Ube3a-YFP* expression was undetectable (silenced) in cultured neurons when paternally inherited (*Ube3a^m+/pYFP^*), but was expressed when maternally inherited (*Ube3a^mYFP/p+^*) ([Fig. 1b](#F1){ref-type="fig"}), with expression increasing from 4 to 10 days *in vitro* (DIV) ([Fig. 1c](#F1){ref-type="fig"}). This significant difference between maternal and paternal UBE3A-YFP protein levels provided a large screening window and a Z'-factor score of 0.58 (determined by statistically comparing antibody-enhanced fluorescence intensities and variations between maternal and paternal UBE3A-YFP signals at DIV10), making our high-content platform suitable for unbiased screening.

To perform the screen, we cultured *Ube3a^m+/pYFP^* neurons for 7 days and then treated these neurons with compounds (10 µM for 72 hours) from multiple small molecule libraries ([Fig. 1d](#F1){ref-type="fig"}, [Supplementary Fig. 1](#SD2){ref-type="supplementary-material"}). In total, we screened 2,306 small molecules in quadruplicate, normalizing values to vehicle-treatment (0.2% DMSO) (for full methods see [Supplementary Methods](#SD11){ref-type="supplementary-material"}; for list of all compounds tested see [Supplementary Table 1](#SD2){ref-type="supplementary-material"}). While methylation and other epigenetic marks are thought to control imprinting of *Ube3a*^[@R9],[@R16]--[@R18]^, to our surprise, none of the commonly used compounds that target the epigenome, including chromatin remodeling drugs and DNA methyltransferase inhibitors, unsilenced the paternal *Ube3a-YFP* allele. A number of compounds were identified as false positives (gray compounds in [Fig. 1d](#F1){ref-type="fig"}) due to their intrinsic fluorescence ([Supplementary Fig. 2](#SD2){ref-type="supplementary-material"}). Our initial screen identified one compound---irinotecan, an FDA-approved camptothecin-based topoisomerase type I inhibitor. Irinotecan lacked intrinsic fluorescence and upregulated UBE3A-YFP fluorescence ([Fig. 1d,e](#F1){ref-type="fig"} and [Supplementary Fig. 3](#SD2){ref-type="supplementary-material"}). Irinotecan (10 µM) also upregulated paternal UBE3A-YFP protein ([Fig. 1f](#F1){ref-type="fig"}) and endogenous UBE3A protein ([Fig. 1g](#F1){ref-type="fig"}) in neuronal cultures from *Ube3a^m+/pYFP^* and *Ube3a^m--/p+^* mice (AS model mice^[@R13]^), respectively.

Many topoisomerase I inhibitors, including irinotecan and the related FDA-approved drug topotecan, are derived from the natural product camptothecin (CPT)^[@R19]^. To explore structure activity relationships, we tested CPT analogs and other topoisomerase inhibitors ([Fig. 2a](#F2){ref-type="fig"}; [Supplementary Figs. 4--10](#SD2){ref-type="supplementary-material"}), all of which lack inherent fluorescence ([Supplementary Fig. 3](#SD2){ref-type="supplementary-material"}). We found that irinotecan and topotecan upregulated paternal UBE3A-YFP in a dose-and time-dependent manner in cultured neurons, with topotecan being 20× more potent than irinotecan ([Fig. 2a,b](#F2){ref-type="fig"}; [Supplementary Fig. 11](#SD2){ref-type="supplementary-material"}). In contrast, an inactive analog of CPT (lactam E-ring-CPT) that does not inhibit topoisomerases^[@R20]^ failed to unsilence the paternal *Ube3a-YFP* allele ([Fig. 2a](#F2){ref-type="fig"}; [Supplementary Fig. 4](#SD2){ref-type="supplementary-material"}). Ten additional topoisomerase I inhibitors unsilenced *Ube3a-YFP* in a dose-dependent manner, including CPT analogs and structurally distinct indenoisoquinolines ([Table 1](#T1){ref-type="table"} and [Supplementary Figs. 4--7](#SD2){ref-type="supplementary-material"}). Furthermore, four structurally distinct topoisomerase II inhibitors (etoposide, dexrazoxane, ICRF-193, and amsacrine) also unsilenced the paternal *Ube3a-YFP* allele ([Table 1](#T1){ref-type="table"} and [Supplementary Figs. 8--10](#SD2){ref-type="supplementary-material"}). Thus, our data with 16 topoisomerase inhibitors and one inactive analog strongly suggest that inhibition of topoisomerase I or II can unsilence the paternal *Ube3a* allele.

We focused our remaining studies on the topoisomerase I inhibitor topotecan because it is approved for use in humans, it unsilenced *Ube3a* in the low nanomolar range, and topotecan (300 nM, 72 h) restored UBE3A protein to wild-type levels in cultured neurons from *Ube3a^m--/p+^* mice ([Fig. 2c](#F2){ref-type="fig"}).

Many topoisomerase inhibitors, including topotecan, covalently link topoisomerases to DNA, forming stable DNA-enzyme complexes that are separable from free topoisomerase enzymes^[@R19]^. Since topotecan inhibits topoisomerase I (TOP1) and *Top1* is expressed at high levels in the developing and adult brain^[@R19],[@R21]^, we focused our subsequent analysis on this enzyme. We found that topotecan (300 nM, 72 h) significantly reduced the amount of free TOP1 ([Fig. 2d](#F2){ref-type="fig"}) in cultured neurons, indicating that topotecan engages its known molecular target at doses that unsilence the paternal *Ube3a* allele.

UBE3A is a HECT (homology to E6 carboxyl terminus) domain E3 ligase that forms a thioester-ubiquitin intermediate in the presence of E1 and E2 enzymes^[@R22]^. This thioester-ubiquitin intermediate is required for HECT domain E3 ligases to mono- and polyubiquitinate their substrates^[@R23]^. Interestingly, we noticed that topotecan (300 nM, 72 hr) upregulated UBE3A protein in *Ube3a^m--/p+^* cultures along with a higher molecular weight form (resolved after running gels for longer times; [Fig. 2e](#F2){ref-type="fig"}). This high molecular weight band was also seen in wild-type (*Ube3a^m+/p+^*) cultures and was lost upon addition of the reducing agent dithiothreitol (DTT) ([Fig. 2e](#F2){ref-type="fig"}). These data suggest that the unsilenced paternal copy of UBE3A is catalytically active and competent to form a thioester-ubiquitin intermediate, just like wild-type, maternal-derived UBE3A^[@R23]^.

To further demonstrate that UBE3A was catalytically active, we immunoprecipitated UBE3A from cultured wild-type and *Ube3a^m--/p+^* neurons (+/− topotecan), then tested these samples for a gel-mobility-shift in the presence or absence of the ubiquitin E2 UBCH7^[@R24]^. Both wild-type (maternal-derived) and topotecan-unsilenced (paternal-derived) UBE3A underwent mobility shifts in the presence of UBCH7 plus free ubiquitin that were abolished by DTT ([Fig. 2f](#F2){ref-type="fig"}). This observation indicates the mobility shift was due to addition of covalent ubiquitin, and demonstrates that topotecan can upregulate a functional UBE3A enzyme.

*Ube3a* is repressed in *cis* by a large antisense transcript (*Ube3a-ATS*) that overlaps the paternal allele of *Ube3a* ([Fig. 2g](#F2){ref-type="fig"})^[@R9],[@R10]^. *Ube3a-ATS* is expressed exclusively from the paternal allele as a result of allele-specific methylation of an imprinting center that overlaps the *Ube3a-ATS* and *Snurf/Snrpn* transcription start site^[@R25]^. We next sought to determine if topotecan regulated *Ube3a* expression through changes in *Ube3a-ATS* expression or altered methylation at the imprinting center. We found that topotecan upregulated expression of *Ube3a* in cultured neurons from *Ube3a^m--/p+^* mice while concomitantly downregulating expression of *Ube3a-ATS and Snrpn* ([Fig. 2h](#F2){ref-type="fig"}). However, topotecan did not alter methylation at the imprinting center ([Fig. 2i](#F2){ref-type="fig"}, [Supplementary Fig. 12](#SD2){ref-type="supplementary-material"}). Taken together, these data suggest that topotecan unsilences paternal *Ube3a* by reducing transcription of a regulatory antisense RNA without appreciably affecting genomic methylation at the imprinting center.

We then sought to determine if topotecan could unsilence the paternal *Ube3a* allele *in vivo*. We first identified a dose that was well tolerated, meaning there were no significant decreases in body weight between the beginning and end of the drug treatments ([Supplementary Fig. 13](#SD2){ref-type="supplementary-material"}). We then administered topotecan (3.74 µg/h) unilaterally into the lateral ventricle of *Ube3a^m+/pYFP^* or *Ube3a^m-/p+^* mice by intracerebroventricular (i.c.v.) infusion for two weeks and then sacrificed the mice either immediately or 5 hr after drug cessation. Strikingly, topotecan unsilenced paternal *Ube3a* in the hippocampus, striatum, and cerebral cortex of the infused hemisphere, but had only a modest effect on the contralateral (non-infused) hemisphere with no effect in the cerebellum ([Fig. 3a--e](#F3){ref-type="fig"}, [Supplementary Figs. 14--15](#SD2){ref-type="supplementary-material"}). Pharmacokinetic analyses demonstrated that a significant amount of topotecan was detectable in the infused hemisphere immediately following treatment whereas low levels were present in the contralateral (non-infused) hemisphere and in cerebellum ([Fig. 3a](#F3){ref-type="fig"}, [Supplementary Fig. 14](#SD2){ref-type="supplementary-material"}). However, a higher dose of topotecan (21.6 µg/h for five days) did unsilence the paternal allele of *Ube3a* in Purkinje neurons of the cerebellum ([Supplementary Fig. 16](#SD2){ref-type="supplementary-material"}). No significant difference in topotecan levels was detected in blood between drug- and vehicle-treated mice (data not shown). Topotecan concentrations significantly declined five hours after cessation of i.c.v. drug delivery ([Fig. 3a](#F3){ref-type="fig"}), indicating that topotecan does not persist and is rapidly removed/metabolized in the brain. Taken together, these pharmacokinetic and pharmacodynamic data suggest that the degree to which topotecan unsilences the paternal *Ube3a* allele is directly correlated with drug concentrations in the brain. Moreover, our data indicate topotecan has the potential to unsilence the paternal *Ube3a* allele throughout the nervous system.

Genomic imprinting is thought to be established only during prescribed germline and embryonic periods of development and imprinted genes typically remain epigenetically regulated throughout life^[@R26]^. Thus, we next sought to determine if topotecan had transient or long-lasting effects on paternal *Ube3a* expression. To test this possibility, we turned to an intrathecal (i.t.) delivery protocol ([Fig. 3f](#F3){ref-type="fig"}) because topotecan ([Fig. 3g](#F3){ref-type="fig"}) and irinotecan (not shown) unsilenced paternal *Ube3a* in a sparse population of lumbar spinal neurons, allowing us to quantify all UBE3A-YFP-positive neurons. Moreover, i.t. delivery has been used to deliver topotecan to the brain in humans^[@R27]^. We found that topotecan (50 nmol/5 µL i.t. once daily, for 10 of 14 days) was well tolerated ([Supplementary Fig. 13](#SD2){ref-type="supplementary-material"}) and significantly increased the number of paternal UBE3A-YFP-positive cells in the lumbar spinal cord of mice ([Fig. 3g,h](#F3){ref-type="fig"}, [Supplementary Fig. 17a](#SD2){ref-type="supplementary-material"}). The vast majority (\>93%) of these UBE3A-YFP-positive cells were NeuN^+^ neurons ([Supplementary Fig. 17a,b](#SD2){ref-type="supplementary-material"}), indicating topotecan unsilences *Ube3a* primarily in neurons *in vivo*. Moreover, the unsilenced paternal UBE3A-YFP protein was expressed at levels comparable to maternal UBE3A-YFP controls ([Supplementary Fig. 17c](#SD2){ref-type="supplementary-material"}). Remarkably, the number of UBE3A-YFP-positive spinal cord neurons remained elevated 12 weeks following cessation of drug treatment ([Fig. 3g,h](#F3){ref-type="fig"}), much longer than the elimination of topotecan from tissue ([Fig. 3a](#F3){ref-type="fig"}). These results indicate that topotecan can enduringly unsilence paternal *Ube3a* in a subset of spinal neurons and suggest that a single course of drug treatment has the capacity to permanently modify expression of *Ube3a*.

In conclusion, we found that topoisomerase inhibitors can unsilence the paternal allele of *Ube3a* and the paternally-derived protein is functional. These findings suggest that topoisomerase inhibitors have the potential to rescue molecular, cellular, and behavioral deficits associated with loss of UBE3A^[@R7],[@R13],[@R28]^. *Ube3a* expression is modestly upregulated in the brain of *Top2b* knockout mice^[@R29]^, providing genetic support that topoisomerases regulate *Ube3a* expression. We also found that topotecan reduced expression of paternal *Snrpn* and *Ipw*, a genomic region whose *deletion* is associated with Prader-Willi syndrome^[@R7],[@R17]^. To what extent topotecan regulates expression of other genes in the brain, including *Igf2r*, *Kcnq1*, and *Gnas* imprinted gene clusters, and whether long-term treatments with topoisomerase inhibitors produce a Prader-Willi-like condition are unknown. However, topotecan and irinotecan are approved for use in patients with cancer, penetrate into the central nervous system, and are well-tolerated when administered chronically to both adult and pediatric patients^[@R27],[@R30]^. Importantly, patients treated with topoisomerase inhibitors do not display symptoms associated with Prader-Willi syndrome. Ultimately, our study indicates that topoisomerase inhibitors regulate gene expression through a transcriptional mechanism and could be used to treat symptoms associated with AS.

Methods Summary {#S1}
===============

All animal procedures were approved by the University of North Carolina at Chapel Hill Animal Care and Use Committee. We used male and female *Ube3a-YFP* knockin mice^[@R15]^, *Ube3a^m--/p+^* mice^[@R13]^, and their age-matched, wild-type controls. High-content screening was performed on a BD Pathway 855 system. UBE3A-YFP was detected for drug screening with an anti-GFP antibody (Novus Biologicals, NB600-308; 1:1000) because intrinsic YFP fluorescence levels were low in cultured neurons and tissue sections. All data are presented as mean ± s.e.m., with sample sizes (*n*) shown in figures or stated in text. Statistical analyses were performed using SigmaPlot 11 (Systat Software). Normality tests (Shapiro-Wilk) and equal variance tests were run and passed (*P*\>0.05) before parametric statistical analyses were run.

[Full methods]{.ul} accompany this paper as [supplementary material](#SD11){ref-type="supplementary-material"}.
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![A small-molecule screen identifies a topoisomerase inhibitor that unsilences the paternal allele of *Ube3a* in neurons\
**a**, High-content screen flowchart. E15.5 cortical neurons with a paternally inherited *Ube3a-YFP* allele were cultured in 384-well plates and treated with small molecules from DIV7--DIV10. Active compounds that unsilence the paternal *Ube3a-YFP* allele were detected with antibody-enhanced fluorescence and high-content imaging. **b**, High-content imaging of DIV7 neurons that inherited *Ube3a-YFP* maternally (m^YFP^/p^+^) or paternally (m^+^/p^YFP^). Nuclei were stained with DAPI. Scale bar = 50 µm. **c**, Mean ± s.e.m. levels of UBE3A-YFP fluorescence in neurons cultured from maternal *Ube3a-YFP* (m^YFP^/p^+^) or wild-type (m^+^/p^+^) mice, normalized to levels in age-matched neurons cultured from paternal *Ube3a-YFP* mice (m^+^/p^YFP^). Two-way ANOVA revealed main effects of genotype, duration, and a genotype-duration interaction (*P*\<0.001); Bonferroni *post hoc* test examined comparisons between maternal and paternal *Ube3a-YFP* mice from DIV4 to DIV10, \**P*\<0.001; *n*=2--6 culture wells/day. **d**, Pie chart depicting categories of the 2,306 screened compounds and graph summarizing presumptive UBE3A-YFP in arbitrary fluorescence units (A.F.U.) after small molecule treatments. Small molecules that were subsequently found to be autofluorescent ([Supplementary Fig. 2](#SD2){ref-type="supplementary-material"}) are depicted in gray. The initial screen identified one active compound, irinotecan (red). **e**, High magnification view of wells treated with vehicle (0.2% DMSO) or 10 µM irinotecan for 72 hr. Neuron density and health is similar in vehicle- and irinotecan-treated cells as evidenced by counterstaining with the nuclear marker DAPI. Scale bar = 100 µm. **f,g**Western blots of cultured cortical neurons probed with GFP or UBE3A antibodies, respectively, ± irinotecan (10 µM for 72h). **f**, \**P*\<0.05; two-tailed *t*-test, *n*=3/group. **g**, \**P*\<0.001, one-way ANOVA with Bonferroni *post hoc, n*=7--8/group. All data are presented as means ± s.e.m.](nihms340278f1){#F1}

![Topotecan unsilences the paternal allele of *Ube3a* and the unsilenced protein is catalytically active\
**a**, Dose-response curves for unsilencing paternal *Ube3a-YFP*. Inactive = lactam E ring-camptothecin. *n*=4/data point. **b**, UBE3A-YFP levels in neurons from *Ube3a^m+/pYFP^* mice increase with duration of topotecan (300 nM) or irinotecan (1 µM) treatment. \**P*\<0.05, oneway ANOVA with Bonferroni *post hoc* tests relative to day zero, *n*=4--8/group. A.F.U.=arbitrary fluorescence units. **c**, Western blots and quantification of UBE3A and the loading control actin. \**P*\<0.05, one-way ANOVA with Bonferroni *post hoc* tests, *n*=4/group. **d**, Quantification of unbound TOP1 and representative western blots. β-tubulin was used as a loading control. One-way ANOVA with Bonferroni *post hoc* tests, \**P*\<0.05; *n*=3/group. **e**, Western blot from vehicle- and topotecan-treated neurons from wild-type (m^+^/p^+^) and maternal *Ube3a*-deficient (m^--^/p^+^) mice. **f**, Western blots examining UBE3A ubiquitin-thioester formation following immunoprecipitation with an anti-UBE3A antibody and *in vitro* ubiquitination in the presence or absence of the ubiquitin conjugating enzyme (E2), UBCH7. All data are presented as means ± s.e.m. **g**, Schematic demonstrating location of 4 primer sets used to probe mRNA expression shown in **h**. **h**, Normalized mRNA levels in cultured *Ube3a*^m--/p+^ neurons following vehicle or 300 nM topotecan. Expression is given as a ratio of expression in drug treated cells to vehicle treated cells, normalized to the housekeeping gene RPL22. \**P*\<0.05 compared to 0 hr, Kruskal-Wallis one-way ANOVA followed by post hoc tests, *n*=4--5 cultures/data point. **i**, Schematic summarizing methylation status of the *Snrpn* promoter region on the maternal and paternal chromosome following treatment with vehicle or 300 nM topotecan (see complete primer 1 data set in [Supplementary Fig.12](#SD2){ref-type="supplementary-material"}). Average methylation status is indicated using a grayscale.](nihms340278f2){#F2}

![Topotecan enduringly unsilences the paternal allele of *Ube3a in vivo*\
**a**, Unilateral delivery of topotecan (i.c.v.) using a mini-osmotic pump into the lateral ventricle of *Ube3a^m+/pYFP^* mice *in vivo*. Two weeks of topotecan infusion (3.74 µg/h) unsilenced the paternal *Ube3a-YFP* allele in the hippocampus of the infused hemisphere near the site of drug delivery, while only modestly unsilencing *Ube3a-YFP* in the contralateral (non-infused) hemisphere. Scale bar = 500 µm. Pharmacokinetic analyses measuring topotecan levels in the infused and non-infused hemisphere immediately (t=0) or five hours (t=5) after cessation of drug delivery. \**P*\<0.05, one-way ANOVA with Bonferroni *post hoc* test, *n*=5--9/group. **b**, Representative sections and **c**, quantification of optical intensity of UBE3A-YFP in hippocampal regions (CA1, CA2/3, and dentate gyrus=DG) of the topotecan-infused hemisphere or the hemisphere of vehicle-treated mice. \**P*\<0.05, Mann-Whitney rank sum test, *n*=5/group. **d**, Representative sections and **e**, quantification of paternal UBE3A-YFP in the striatum following i.c.v. infusion of topotecan. \**P*\<0.05, two-tailed *t* test, *n*=4/group. **f**, Schematic depicting schedule for i.t. delivery of topotecan (50 nmol/day for 10 of 14 days) and endpoints (arrows) immediately, 4 weeks, and 12 weeks after cessation of drug. **g,h** Topotecan (i.t.) increased the number of UBE3A-YFP-positive spinal neurons compared to vehicle, and the unsilencing of *Ube3a-YFP* was maintained for at least 12 weeks. \**P*\<0.001, one-way ANOVA with Bonferroni post hoc test, n=7--8/group.](nihms340278f3){#F3}

###### 

Efficacies and potencies of topoisomerase inhibitors for unsilencing the paternal allele of *Ube3a-YFP* in cultured neurons.

  --------------------------------------------------------------------------------------------
  Compound                                                      Potency\         Efficacy\
                                                                EC~50~ (nM)      E~max~\
                                                                                 (fold over\
                                                                                 vehicle)
  ------------------------------------------------------------- ---------------- -------------
  **Camptothecin derivatives**                                                   

       7-Ethyl-Camptothecin (7-Ethyl-C PT)                      7.2 ± 2.3        1.70 ± 0.04

       7-Ethyl-10-H ydroxy-CPT                                  11 ± 3.2         1.99 ± 0.06

       10-H ydroxy-CPT                                          14 ± 5.7         1.82 ± 0.08

       Belotecan (CKD 602)                                      19 ± 4.4         1.88 ± 0.05

       Camptothecin (CPT)                                       21 ± 3.8         2.11 ± 0.05

       Topotecan[\*](#TFN1){ref-type="table-fn"}                54 ± 3.4         2.25 ± 0.05

       Rubitecan (9-Nitro-CPT)                                  62 ± 18          2.09 ± 0.09

       Irinotecan[\*](#TFN1){ref-type="table-fn"}               994 ± 13         2.17 ± 0.05

       Silatecan (DB67)                                         2,244 ± 171      1.65 ± 0.05

       Lactam E ring-CPT (inactive)                             inactive         inactive

  **Indenoisoquinoline derivatives**                                             

       NSC725776                                                10 ± 1.6         1.76 ± 0.03

       NSC706744                                                11 ± 3.2         1.84 ± 0.07

       NSC724998                                                14 ± 2.2         1.69 ± 0.03

  **Podophyllotoxin derivative**                                                 

       Etoposide[\*](#TFN1){ref-type="table-fn"}                1,600 ± 980      1.68 ± 0.04

  **Bis-dioxopiperazine derivatives**                                            

      ICRF-193                                                  205 ± 70         2.21 ± 0.09

       Dexrazoxane (ICRF-187)[\*](#TFN1){ref-type="table-fn"}   2,0470 ± 1,450   1.82 ± 0.05

  **Aminoacridine derivative**                                                   

      Amsacrine                                                 27 ± 5.2         1.74 ± 0.06
  --------------------------------------------------------------------------------------------

FDA-approved compounds
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